A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein–Barr virus in adults with human immunodeficiency virus-1

被引：0

作者：

R Newton

L Carpenter

D Casabonne

V Beral

A Babiker

J Darbyshire

I Weller

R Weiss

A Kwan

D Bourboulia

F Munoz

D Lagos

C Boshoff

机构：

[1] Epidemiology & Genetics Unit,Department of Health Sciences

[2] Area 3,Department of Public Health

[3] Seebohm Rowntree Building,Division of Infection and Immunity

[4] Cancer Research UK Cancer Epidemiology Unit,undefined

[5] University of Oxford,undefined

[6] University of Oxford,undefined

[7] MRC Clinical Trials Unit,undefined

[8] University College London,undefined

[9] Centre for Sexual Health and HIV Research,undefined

[10] University College London,undefined

[11] Wohl Virion Centre,undefined

[12] University College London,undefined

[13] Cancer Research UK Viral Oncology Group,undefined

[14] Wolfson Institute of Medical Sciences,undefined

来源：

British Journal of Cancer | 2006年 / 94卷

关键词：

Kaposi's sarcoma; non-Hodgkin's lymphoma; Epstein–Barr virus; Kaposi's sarcoma-associated herpesvirus; human immunodeficiency virus;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Antibody titres against Kaposi's sarcoma associated herpesvirus (KSHV or human herpesvirus 8 (HHV-8)) and Epstein–Barr virus (EBV) were examined in people who subsequently developed Kaposi's sarcoma and non-Hodgkin's lymphoma, within randomised controlled trials of antiretroviral therapy in adults infected with the human immunodeficiency virus-1 (HIV). For each case of Kaposi's sarcoma (n=189) and each case of non-Hodgkin's lymphoma (n=67), which developed after randomisation, one control was randomly selected from other trial participants, after matching for age, sex, ethnicity, mode of HIV transmission, type of treatment received and period of follow-up. Using sera taken an average of two and a half years before the diagnosis of cancer, titres of antibodies against KSHV latent (LANA) and lytic (K8.1) antigens and against EBV (VCA) antigens were investigated in relation to subsequent risks of cancer by calculating odds ratios (OR) using conditional logistic regression. Latent antibodies against KSHV were detectable among 38% (72 out of 189) of Kaposi's sarcoma cases and 12% (23 out of 189) of their controls (OR=4.4, 95% confidence intervals (CI) 2.3–8.3, P<0.001). The OR for Kaposi's sarcoma increased with increasing antilatent KSHV antibody titre (χ21 for trend=32.2, P<0.001). Lytic antibodies against KSHV were detectable among 33% (61 out of 187) of Kaposi's sarcoma cases and 19% (36 out of 187) of their controls (OR=2.0, 95% CI 1.2–3.4, P=0.003) and the OR for Kaposi's sarcoma increased with increasing antilytic KSHV antibody titre (χ21 for trend=6.2, P=0.02). Virtually, all cases and controls had anti-EBV antibodies detected and the OR for non-Hodgkin's lymphoma associated with a doubling of the anti-EBV antibody titre was estimated to increase by a multiplicative factor of 1.3 (95% CI 0.9–1.7, P=0.1). Kaposi's sarcoma was not associated with antibody levels against EBV (P=0.4) and non-Hodgkin's lymphoma was not associated with antibodies against KSHV (latent P=0.3; lytic P=0.5). Adjustment for CD4 count at the time of sample collection made no material difference to any of the results. In conclusion, among human immunodeficiency virus infected people, high levels of antibodies against KSHV latent and lytic antigens are strongly associated with subsequent risk of Kaposi's sarcoma but not non-Hodgkin's lymphoma. Antibody titre to EBV does not appear to be strongly associated with subsequent risk of Kaposi's sarcoma or non-Hodgkin's lymphoma in HIV infected people.

引用

页码：1504 / 1509

页数：5

共 158 条

[1]

Akre O(1999)Epstein Barr virus and cytomegalovirus in relation to testicular cancer risk: a nested case–control study Int J Cancer 82 1-5

[2]

Lipworth L(1998)Overview of the epidemiology of immunodeficiency associated cancers Monogr Natl Cancer Inst 23 1-6

[3]

Tretli S(2004)Short and long-term effects of highly active antiretroviral therapy of Kaposi's sarcoma-associated herpesvirus immune responses and viraemia AIDS 18 485-493

[4]

Linde A(2001)Seroepidemiology and molecular epidemiology of Kaposi's sarcoma-associated herpesvirus among Jewish population groups in Israel J Natl Cancer Inst 93 194-202

[5]

Engstrand L(1967)Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line J Virol 1 1045-1051

[6]

Adami HO(2000)Interaction of human immunodeficiency virus 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma J Iinvest Dermatol 181 1940-1949

[7]

Melbye M Andersen A(2002)Highly sensitive assay for human herpesvirus 8 antibodies that uses multiple antigenic peptide derived from open reading frame K8.1 J Clin Micorbiol 40 325-329

[8]

Ekbom A(1993)Increased risk of malignant lymphoma indicated by elevated Epstein–Barr virus antibodies – a prospective study Cancer Causes Control 4 187-192

[9]

Beral V(1991)Epstein–Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma Int J Cancer 49 387-393

[10]

Newton R(2003)Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda Br J Cancer 89 502-504

← 1 2 3 4 5 6 7 8 9 10 →